Mutation of the GRB2-binding site at Y177 in p210BCR-ABL1 fails to induce a CML-like disease [24] and enhances sensitivity to imatinib by inhibiting RAS and protein kinase B (PKB, also named AKT) activation in CML [31]. Here, GRB2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.